Venaxis (APPY) says the external Data & Safety Monitoring Board created for the trial of the company's APPY1 Test has recommended continuing the study based on two futility analyses that were carried out on 579 patients. The trial will enroll a total of 2,000 patients for the APPY1 Test, which identifies patients who are at low risk of appendicitis. Shares are -5.1%, possibly because Venaxis expects to complete recruitment by the end of 2013 rather than in August, as previously forecast, and file for FDA clearance in Q1 2014. (PR)
Venaxis (APPY) says the external Data & Safety Monitoring Board created for the trial of the...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs